A friend mentions his testosterone came back at 280 ng/dL and he's already looking up clinics. You had a similar number on a lab you got last year, but nobody ever brought up treatment. So which one of you actually qualifies for TRT?
The honest answer is that a single number rarely settles it. Testosterone replacement therapy candidacy, according to the major clinical guidelines, depends on a combination of confirmed low levels, consistent symptoms, and a clinician ruling out other explanations. This guide walks through exactly what those guidelines require, where they disagree, and what a bloodwork-driven evaluation actually looks like.
Table of Contents
- What a 'Low Testosterone' Lab Result Actually Means
- The Two-Part Test Every Major Guideline Requires: Symptoms Plus Labs
- Testosterone Cutoffs: How AUA, Endocrine Society, and ACP Compare
- Symptoms That Count Toward a Hypogonadism Diagnosis
- Who Guidelines Say TRT Is Not Appropriate For
- Required Bloodwork Before a Clinician Confirms TRT Candidacy
- Age-Related Low Testosterone: Why the ACP Guideline Is More Cautious
- How a LodeRx Intake Evaluates Candidacy
What a 'Low Testosterone' Lab Result Actually Means
Total testosterone (TT) is the standard first measurement in any hormone workup. It reflects the total amount of testosterone circulating in the blood, both bound to proteins and free. On its own, a low TT number tells a clinician relatively little, because testosterone levels move throughout the day and vary meaningfully between labs and assay methods.
The American Urological Association's Testosterone Deficiency Guideline identifies a total testosterone below 300 ng/dL as a reasonable cut-off for further evaluation (auanet.org). That word "reasonable" matters. The AUA frames it as a supporting threshold, not an automatic diagnosis. A single low draw opens the door to further workup; it does not close the case.
Two practical details shape how that number gets collected:
- Morning fasting draws are standard, because testosterone follows a diurnal rhythm and peaks earlier in the day, then declines. A testosterone level drawn at 4 p.m. can read lower than the same man's level drawn at 8 a.m., which is why afternoon labs can mislead a candidacy discussion.
- Free testosterone is a secondary marker some clinicians check when total testosterone sits near the borderline, since binding-protein levels can shift how much testosterone is actually bioavailable versus how much shows up on a total count.
The Two-Part Test Every Major Guideline Requires: Symptoms Plus Labs
The Endocrine Society's 2018 Clinical Practice Guideline, authored by Bhasin and colleagues, sets the core rule that most TRT-prescribing clinicians in the United States still follow: a diagnosis requires both consistent symptoms and confirmed low testosterone on repeated testing (academic.oup.com).
That combination has a name. Hypogonadism describes testosterone deficiency that has a recognizable clinical cause or consequence, not simply a number that falls under a lab's reference range. A lab flag by itself is not a diagnosis.
Guidelines from both the AUA and the Endocrine Society call for at least two separate morning measurements confirming a consistently low result before a clinician considers the diagnosis established. One low draw is a data point; two is a pattern.
A low number without symptoms, or symptoms without a confirmed low number, does not meet candidacy criteria under either guideline. Both pieces have to line up before TRT becomes a reasonable conversation.
Testosterone Cutoffs: How AUA, Endocrine Society, and ACP Compare
The three guideline bodies most often cited in TRT discussions do not use identical language or identical numbers. Seeing them side by side makes clear why a clinician interprets a lab value in context rather than checking it against one universal line.
| Guideline Body | Testosterone Threshold | Testing Requirement | Population Focus |
|---|---|---|---|
| AUA | Below 300 ng/dL (reasonable cut-off) | Two morning measurements | General adult men with symptoms |
| Endocrine Society | Consistent with assay-specific lower limit | Repeated, standardized measurement | Men with symptoms and signs of deficiency |
| ACP | No fixed universal cutoff endorsed | Individualized, shared decision-making | Age-related low testosterone in older men specifically |
Sources: auanet.org, academic.oup.com, acponline.org.
The three bodies do not use identical numbers, which is exactly why a clinician reads a lab result against a patient's symptoms and the relevant guideline population, rather than treating a single line item as a verdict.
Symptoms That Count Toward a Hypogonadism Diagnosis
Guidelines weigh a fairly specific set of symptom categories rather than a generic "I feel off" complaint. The categories most consistently referenced include:
- Reduced libido
- Erectile dysfunction, including fewer morning erections
- Loss of body hair
- Reduced muscle mass
- Increased body fat
- Low energy
- Mood changes
Not all of these carry equal weight. Per the Endocrine Society's Clinical Practice Guideline, nonspecific symptoms like fatigue or low mood are considered but weighed less heavily on their own, because they overlap with sleep disorders, depression, thyroid conditions, and a long list of other causes unrelated to testosterone (academic.oup.com).
Specific sexual symptoms, particularly reduced morning erections and low libido, are considered more predictive of true testosterone deficiency than general low-energy complaints. A clinician evaluating candidacy will typically also review a patient's sleep quality, current medication list, and body composition before attributing any of these symptoms to testosterone specifically, since several common medications and untreated sleep apnea can produce a nearly identical symptom picture.
Who Guidelines Say TRT Is Not Appropriate For
Candidacy criteria work in both directions. The AUA and Endocrine Society guidelines both reference a set of situations where testosterone therapy is not appropriate, at least not without further workup first:
- Untreated prostate cancer
- Elevated PSA without a completed urologic workup
- Uncontrolled heart failure
- A near-term desire for fertility, without a fertility-preserving plan already in place
A 2022 individualized-approach paper by Dobs and colleagues notes that PSA should be evaluated before starting testosterone therapy in men 40 and older who do not have a prostate cancer history, reinforcing that a PSA check is not optional in this age group (pmc.ncbi.nlm.nih.gov).
Men actively trying to conceive are typically routed to fertility-specific evaluation first. Exogenous testosterone can suppress the body's natural sperm production, which makes it a poor starting point for someone planning a pregnancy in the near term.
It's also worth stating plainly: a normal-range testosterone result paired with real symptoms usually means investigating other causes, not skipping straight to treatment. Guidelines do not support treating symptoms with testosterone when the testosterone level itself is not actually low.
Required Bloodwork Before a Clinician Confirms TRT Candidacy
A guideline-based workup is built around a specific panel, not a single test. The standard pre-treatment panel generally includes:
- Two morning total testosterone draws
- Free testosterone or SHBG, when total testosterone sits near the borderline
- PSA, in men 40 and older
- A complete blood count
- A metabolic panel
The complete blood count matters for a specific reason: testosterone therapy can raise red blood cell counts, so a baseline hematocrit gives a clinician a comparison point once monitoring starts. Without a baseline, there's nothing to measure change against.
No clinician should confirm testosterone therapy candidacy from a single lab value pulled off an at-home finger-stick kit without a confirmatory venous draw. Finger-stick testosterone tests are convenient for a first look, but they are not the standard used in any of the guidelines discussed here.
For a closer look at how a full baseline panel gets structured before any treatment discussion, see the LodeRx bloodwork hub.
Age-Related Low Testosterone: Why the ACP Guideline Is More Cautious
The American College of Physicians' 2020 guideline takes a notably more conservative stance than the AUA or Endocrine Society documents. It applies specifically to adult men with age-related low testosterone, and it emphasizes shared decision-making over any fixed treatment threshold (acponline.org). Rather than naming a cutoff number, the ACP asks clinicians and patients to weigh symptoms, goals, and risk tolerance together.
The ACP also recommends against letting TRT candidacy alone drive routine PSA-based prostate cancer screening decisions, keeping those two clinical questions separate rather than bundling them.
That caution reflects a real clinical distinction. Age-related decline in testosterone is a different phenomenon than hypogonadism caused by pituitary or testicular disease. The latter tends to involve a clearer underlying cause and a more predictable response to treatment; the former is a gradual, population-level trend where the line between "low for this man" and "normal aging" is genuinely harder to draw. That's part of why guidelines treat the two populations differently rather than applying one rule to both.
To see how candidacy fits into a longer-term hormone care plan once a workup is complete, visit the LodeRx TRT hub.
How a LodeRx Intake Evaluates Candidacy
LodeRx is a marketing brand. Clinical evaluation, including the guideline-based candidacy review described throughout this article, is performed by EliteCare, a network of state-licensed clinicians practicing across all 50 states. LodeRx itself does not diagnose, prescribe, or dispense medication. When a testosterone prescription is appropriate, it is prescribed by a licensed clinician and compounded and dispensed by a 503A partner pharmacy such as RxAve.
LodeRx holds a LegitScript Healthcare Merchant Certification, effective July 30, 2026, certificate number 50431222. That certification reflects healthcare merchant compliance and accreditation standards; it is not a medical endorsement, and it is not FDA approval of any compounded formulation.
For men thinking about hormone health as part of a broader picture, rather than a single lab value, the LodeRx longevity hub covers how baseline tracking fits into ongoing care.
Frequently Asked Questions
What testosterone level qualifies for TRT?
Most guidelines point to a total testosterone below 300 ng/dL as a reasonable supporting threshold, per the American Urological Association's Testosterone Deficiency Guideline. But a low number alone is not enough; guidelines also require consistent symptoms and at least two confirmed morning lab draws before a clinician considers a diagnosis of testosterone deficiency established.
Is 36 too early to start TRT?
Age alone does not determine candidacy. Guidelines from the Endocrine Society and AUA focus on confirmed low testosterone plus consistent symptoms, regardless of age, though a clinician evaluating a younger man typically investigates underlying causes, such as pituitary, testicular, or lifestyle factors, before considering testosterone therapy, since age-related decline guidelines like the ACP's apply to a different population.
Do I need two separate testosterone tests to qualify for TRT?
Yes, under both the AUA and Endocrine Society guidelines. Testosterone naturally fluctuates and follows a diurnal rhythm, so a single afternoon draw is not considered sufficient. Standard practice is two morning fasting measurements confirming a consistently low result before a clinician finalizes a hypogonadism diagnosis.
What symptoms matter most when a clinician evaluates TRT candidacy?
Sexual symptoms carry the most diagnostic weight: reduced libido, fewer morning erections, and erectile dysfunction. Nonspecific complaints like fatigue or low mood are considered but weighed less heavily alone, per the Endocrine Society's Clinical Practice Guideline, because they overlap with many other conditions unrelated to testosterone.
Can you qualify for TRT with normal-range total testosterone but low free testosterone?
It's possible in select cases. Some clinicians check free testosterone or SHBG when total testosterone sits near the borderline, since conditions affecting binding proteins can mask a true deficiency. This is an individualized judgment call rather than a universal guideline cutoff, and it should be made with a clinician reviewing the full panel.
Next Step
Guideline criteria are a starting point, not a self-diagnosis tool. If your symptoms and lab history line up with what's described here, the next concrete step is a full bloodwork panel reviewed by a licensed clinician, not a single home test. You can review what a baseline hormone panel looks like on the LodeRx bloodwork hub before deciding whether an intake conversation with EliteCare makes sense for you.